Marketing-authorisation holder
Axsome Malta
3 medicines in 2 countries, as authorisation holder.
Medicines
Every medicine in the registers under its name, current ones first.
3 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| SUNOSI150 mg · Tablet | Solriamfetol | Canada | Marketed | 2021 |
| SUNOSI150mg base | 75mg base · Tablet | Solriamfetol | United States | Marketed | 2019 |
| SUNOSI75 mg · Tablet | Solriamfetol | Canada | Marketed | 2021 |
Countries
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Canada | 2 | 2 | 0 | CompaniesAll medicines |
| United States | 1 | 1 | 0 | CompaniesAll medicines |
Therapeutic areas
The ATC groups most of its medicines belong to, largest first.
- PsychoanalepticsNervous system · ATC N06B
Top substances
The active substances in most of its medicines.
Names in the registers
How the registers spell it, normalised: legal forms, accents and capitals removed.
- axsome malta ltd
Sources and licences
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Report an error or request removalCorrections from the company itself are welcome.
At a glance
- Type
- Marketing-authorisation holder
- Medicines
- 3
- Countries
- 2
- Roles
- Authorisation holder